<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Meyer A</submitter><funding>BLRD VA</funding><funding>Department of Veteran’s Affairs</funding><funding>Innovative Research Award from the Rheumatology Research Foundation</funding><funding>NIAID NIH HHS</funding><funding>Medical Research Council</funding><funding>Foundation for the National Institutes of Health</funding><pagination>483-495</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10314955</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>82(4)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Syntenin-1, a novel endogenous ligand, was discovered to be enriched in rheumatoid arthritis (RA) specimens compared with osteoarthritis synovial fluid and normal synovial tissue (ST). However, the cellular origin, immunoregulation and molecular mechanism of syntenin-1 are undescribed in RA.&lt;h4>Methods&lt;/h4>RA patient myeloid and lymphoid cells, as well as preclinical models, were used to investigate the impact of syntenin-1/syndecan-1 on the inflammatory and metabolic landscape.&lt;h4>Results&lt;/h4>Syntenin-1 and syndecan-1 (SDC-1) co-localise on RA ST macrophages (MΦs) and endothelial cells. Intriguingly, blood syntenin-1 and ST SDC-1 transcriptome are linked to cyclic citrullinated peptide, erythrocyte sedimentation rate, ST thickness and bone erosion. Metabolic CD14&lt;sup>+&lt;</pubmed_abstract><journal>Annals of the rheumatic diseases</journal><pubmed_title>Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells.</pubmed_title><pmcid>PMC10314955</pmcid><funding_grant_id>MERIT Award BX002286</funding_grant_id><funding_grant_id>G0800648</funding_grant_id><funding_grant_id>R41 AI147697</funding_grant_id><funding_grant_id>I01 BX002286</funding_grant_id><funding_grant_id>NIH R01 AI167155</funding_grant_id><funding_grant_id>R01 AI167155</funding_grant_id><funding_grant_id>NIH R41 AI147697</funding_grant_id><pubmed_authors>Lewis M</pubmed_authors><pubmed_authors>Umar S</pubmed_authors><pubmed_authors>Jetanalin P</pubmed_authors><pubmed_authors>Shahrara S</pubmed_authors><pubmed_authors>Sweiss N</pubmed_authors><pubmed_authors>Van Raemdonck K</pubmed_authors><pubmed_authors>Al-Awqati M</pubmed_authors><pubmed_authors>Volin MV</pubmed_authors><pubmed_authors>Zanotti B</pubmed_authors><pubmed_authors>Nijim W</pubmed_authors><pubmed_authors>Chang HJ</pubmed_authors><pubmed_authors>Arami S</pubmed_authors><pubmed_authors>Pitzalis C</pubmed_authors><pubmed_authors>Schett G</pubmed_authors><pubmed_authors>Meyer A</pubmed_authors><pubmed_authors>Sienes RE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells.</name><description>&lt;h4>Objectives&lt;/h4>Syntenin-1, a novel endogenous ligand, was discovered to be enriched in rheumatoid arthritis (RA) specimens compared with osteoarthritis synovial fluid and normal synovial tissue (ST). However, the cellular origin, immunoregulation and molecular mechanism of syntenin-1 are undescribed in RA.&lt;h4>Methods&lt;/h4>RA patient myeloid and lymphoid cells, as well as preclinical models, were used to investigate the impact of syntenin-1/syndecan-1 on the inflammatory and metabolic landscape.&lt;h4>Results&lt;/h4>Syntenin-1 and syndecan-1 (SDC-1) co-localise on RA ST macrophages (MΦs) and endothelial cells. Intriguingly, blood syntenin-1 and ST SDC-1 transcriptome are linked to cyclic citrullinated peptide, erythrocyte sedimentation rate, ST thickness and bone erosion. Metabolic CD14&lt;sup>+&lt;</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-04T19:58:08.039Z</modification><creation>2025-04-04T19:58:08.039Z</creation></dates><accession>S-EPMC10314955</accession><cross_references><pubmed>36593091</pubmed><doi>10.1136/ard-2022-223284</doi></cross_references></HashMap>